Impact of fluoroquinolone exposure on the diagnosis and prognosis of tuberculosis in immunocompromised patients: a propensity-score-matched, competing risk analysis

Fluoroquinolone exposure in immunocompromised patients with TB did not adversely affect diagnostic timelines or mortality outcomes.

Authors

Hyeon Mu Jang (ORCID: https://orcid.org/0009-0003-0132-5261)
Sang‐Oh Lee (ORCID: https://orcid.org/0000-0003-1381-8787)
Euijin Chang (ORCID: https://orcid.org/0000-0001-7417-0318)
Jiwon Jung (ORCID: https://orcid.org/0000-0003-4333-3270)
Seongman Bae (ORCID: https://orcid.org/0000-0001-6375-3657)
Sang‐Ho Choi (ORCID: https://orcid.org/0000-0002-4972-4531)
Sung‐Han Kim (ORCID: https://orcid.org/0000-0002-6596-8253)
Min Jae Kim (ORCID: https://orcid.org/0000-0003-3241-530X)
Yang Soo Kim (ORCID: https://orcid.org/0000-0002-6785-8824)
Sung‐Woon Kang (ORCID: https://orcid.org/0000-0002-9001-5198)
Yong Pil Chong (ORCID: https://orcid.org/0000-0003-1672-3185)